questionnaires of fatigue (FACIT-FATIGUE), quality of life (EQ-5D-5L), disability (HAQ) and a Global Health Status Scale (GHS) (0–100). Biostatistical analysis was performed using the multivariate analysis of variance by Pillai test. Results 54 SLE patients (91.84% female) with a mean age at diagnosis of 27.55±13.21 years and a mean time of disease evolution of 20.45±9.7 years were included. Mean SLEDAI score was 6.63±6.89, with a 37.04% of patients with SLE- DAI>6. The 64.66% of patients were under glucocorticoid treatment, 38.77% under immunosuppressants (methotrexate, azatioprine or mycophenolate) and 51.02% under antimalarials. Patients showed a mean score of 34.02±12.38 in FACIT- FATIGUE, 0.72±0.26 in EQ-5D-5L, 0.62±0.71 in HAQ and 64.02±25.93 in GHS. Statistical analysis showed correlation among high SLEDAI scores and low scores of EQ-5D-5L, FACIT-FATIGUE and GHS, and an increment in HAQ, considering as correcting factors the age, years of disease evolution, glucocorticoid treat- ment, antimalarials and immunosuppressants (P=0.0107). Conclusions We observed a correlation between PROs-QL full- filled by SLE patients with the clinical activity of the disease, independently of glucocorticoid treatment, antimalarials and immunosuppressants, the age and the disease evolution. P181 COMPARISON OF SLEDAI-2K AND SLEDAI-2KG (GLUCOCORTICOID) INDEXES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) 1 Selma Sari, 2 Bahar Artim Esen, 2 Ahmet Gül, 2 Lale Öcal, 2 Murat İnanç. 1 Dept. of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul; 2 Dept. of Internal Medicine, Division of Rheumatology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey 10.1136/lupus-2020-eurolupus.223 Background Disease activity measurement in SLE can be per- formed with SLEDAI based on clinical and laboratory findings. The new SLEDAI-2K-glucocorticoid index (SLEDAI-2KG) devel- oped from SLEDAI-2K calculates disease activity by taking into account the amount of glucocorticoids used. In this cross-sec- tional prospective study, two indexes were compared in consecu- tive SLE patients. Methods Seventy-nine SLE patients were included into the study. Disease activity was evaluated using SLEDAI-2K and SLEDAI-2KG. Patients were grouped as SLEDAI = 0 (group 1), lupus low disease activity status (LLDAS) (group 2) and active disease (group 3). LLDAS was defined as:(SLEDAI)-2K £ 4, with no activity in major organ systems and no haemo- lytic anaemia or gastrointestinal activity; no new lupus disease activity; PGA (scale 0– 3) £1; a current prednisolone dose £7.5 mg daily; and stable maintenance doses of immunosup- pressive drugs and approved biological agents. Results Table 1 shows clinical features of SLE patients. Eighty-six percent of the patients were female. Median age 34 (range 18–74), median disease duration 36 (0–436) months. Thirty-five percent of the patients had renal activity, 7% had malar rash, 12% had alopecia, 2 (2.5%), 8% had thrombocytopenia, 8%had leucopenia, 3.8% had fever. Sixty- one percent of the patients had hypocomplementemia and 29% had anti-dsDNA positivity. Glucocorticoids were used by 63 patients and the median prednisone dose was 16 (0– 75) mg. The median of SLEDAI-2K score of 79 patients was 4 (range 0–24) and the median of SLEDAI-2KG score was 7 (range 0–25). Significant positive correlation was found between SLEDAI-2K and SLEDAI-2KG scores(r=0,93, p<0,01). When SLEDAI-2K and SLEDAI-2KG were com- pared, the proportion of patients with disease activity 0 was 24% and 9%, LLDAS 20% and 27%, and active patients 56% and 64%, respectively. Conclusion Although there was a significant correlation between SLEDAI-2K and SLEDAI-2KG, more patients were defined as active with SLEDAI-2KG. Considering the impor- tance of reducing glucocorticoid dose in clinical trials in the assessment of treatment response, SLEDAI-2KG may provide a more precise treatment response. Prospective studies are required to investigate the importance of SLEDAI-2KG in long-term prognosis of SLE patients. P182 ORGAN DAMAGE IN CROATIAN COHORT OF PATIENTS WITH CHILDHOOD ONSET SYSTEMIC LUPUS ERYTHEMATOSUS 1 Nastasia Kifer, 1 Mario Sestan, 1 Emilija Hosticka, 1 Maja Novoselec, 1 Mateja Batnozic Varga, 1 Ivan Padjen, 1 Marijan Frkovic, 2 Domagoj Kifer, 1 Branimir Anic, 1 Drago Batinic, 1 Kristina Potocki, 1 Ivan Malcic, 1 Marija Jelusic. 1 University of Zagreb School of Medicine, Zagreb; 2 Faculty of Pharmacy and Biochemistry, University of Zagreb, Zagreb, Croatia 10.1136/lupus-2020-eurolupus.224 Background Our aim was to explore the correlation between the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI 2K) at the time of diagnosis and the SLICC/ACR damage index (SDI) of patients at their last follow up, to examine organ damage and to predict the risk of organ dam- age occurrence in time. Methods The retrospective study included children with child- hood onset systemic lupus erythematosus (cSLE) treated from 1991 to 2017 at University Hospital Centre Zagreb. Abstract P181 Table 1 Demographic and clinical characteristics of SLE patients SLE, n=79 Male/Female, 68/11 Age, years (median, range) 34 (18–74) Disease duration, months (median, range) 36 (0–436) Manifestations Vasculitis, n (%) 10 (12,7) Arthritis, n (%) 5 (6,3) Renal activity, n (%) 28 Proteinuria, n (%) 26 Hemolytic anemia, n (%) 6 (7,5) Trombositopenia, n (%) 7 (8,9) Autoantibodies ANA, n (%) 74 (93,7) Anti-dsDNA, n (%) 23 (29,1) C3 levels (mg/dl, median, range) 81 (34–185) C4 levels, (mg/dl, median, range) 2 (2–42) SLEDAI score (median, range) 4 (0–24) SLEDAI-2KG score (median, range) 7 (0–25) Treatment Prednisone, n (%) 63 (79,7) Azathioprine, n (%) 21 (26,6) Antimalarial, n (%) 52 (62,8) Mycophenolate, n (%) 21 (26,6) Abstracts A118 Lupus Science & Medicine 2020;7(Suppl 1):A1–A131 on July 24, 2020 by guest. Protected by copyright. http://lupus.bmj.com/ Lupus Sci Med: first published as 10.1136/lupus-2020-eurolupus.224 on 23 March 2020. Downloaded from